Anixa Biosciences reports extended patient survival, approval for higher CAR-T doses
Anixa Biosciences said that 7 of 12 patients treated in its Phase 1 ovarian cancer CAR-T trial have lived beyond their expected median survival, and that regulators approved a protocol amendment allowing dose escalation. The company describes the survival evidence as encouraging but anecdotal, and says the trial is designed primarily to demonstrate safety. The filing contains no financial figures.
Key points
- 12 patients have been treated at four dosage levels; 7 have lived beyond their expected median survival of about three to four months
- One patient survived 28 months, and three have survived more than one year (17, 15 and 14 months)
- Amended protocol allows dosing up to 1×10⁹ cells/kg, from the original range of 1×10⁵ to 1×10⁷; no dose-limiting toxicities observed to date
- Dr. Amit Kumar will discuss the trial at a Water Tower Research fireside chat on February 10, 2026, at 11:00am ET
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.